Age: 60.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: COVID-19 immunisation, Exposure to SARS-CoV-2, Inappropriate schedule of product administration, Influenza like illness, Interchange of vaccine products
Clinical narrative: tenderness; Patient received the vaccine in his left arm and had left arm soreness; Patient received the second vaccine series dose as the Pfizer vaccine because the Moderna vaccine was not available to receive; The patient did not get his second dose in early February 2023 because he had flu like symptoms, on 11-APR-2023, Patient received the second vaccine series dose as the Pfizer vaccine; Patient received his first Moderna Covid-19 vaccine on January 9, 2023 and Patient received the second vaccine series dose as the Pfizer vaccine; Patient received his first Moderna Covid-19 vaccine on January 9, 2023 and Patient received the second vaccine series dose as the Pfizer vaccine; The patient was exposed to a person who had Covid-19 in early March; chest cold; he had flu like symptoms; This spontaneous case was reported by a patient and describes the occurrence of INFLUENZA LIKE ILLNESS (he had flu like symptoms), LOWER RESPIRATORY TRACT INFECTION (chest cold), TENDERNESS (tenderness), EXPOSURE TO SARS-COV-2 (The patient was exposed to a person who had Covid-19 in early March) and PAIN IN EXTREMITY (Patient received the vaccine in his left arm and had left arm soreness) in a 60-year-old male patient who received mRNA-1273 (Spikevax) (batch no. AS7171B) for COVID-19 prophylaxis. The occurrence of additional non-serious events is detailed below.    Co-suspect product included non-company product TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) for an unknown indication.    No Medical History information was reported.    On 09-Jan-2023, the patient received first dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form. On 11-Apr-2023, the patient received second dose of TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) (unknown route) 1 dosage form. In February 2023, the patient experienced INFLUENZA LIKE ILLNESS (he had flu like symptoms). In March 2023, the patient experienced LOWER RESPIRATORY TRACT INFECTION (chest cold) and EXPOSURE TO SARS-COV-2 (The patient was exposed to a person who had Covid-19 in early March). On 11-Apr-2023, the patient experienced INTERCHANGE OF VACCINE PRODUCTS (Patient received his first Moderna Covid-19 vaccine on January 9, 2023 and Patient received the second vaccine series dose as the Pfizer vaccine), COVID-19 IMMUNISATION (Patient received his first Moderna Covid-19 vaccine on January 9, 2023 and Patient received the second vaccine series dose as the Pfizer vaccine) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (The patient did not get his second dose in early February 2023 because he had flu like symptoms, on 11-APR-2023, Patient received the second vaccine series dose as the Pfizer vaccine). On an unknown date, the patient experienced TENDERNESS (tenderness), PAIN IN EXTREMITY (Patient received the vaccine in his left arm and had left arm soreness) and PRODUCT AVAILABILITY ISSUE (Patient received the second vaccine series dose as the Pfizer vaccine because the Moderna vaccine was not available to receive). The patient was treated with AZITHROMYCIN for Chest cold, at an unspecified dose and frequency. At the time of the report, INFLUENZA LIKE ILLNESS (he had flu like symptoms), LOWER RESPIRATORY TRACT INFECTION (chest cold), EXPOSURE TO SARS-COV-2 (The patient was exposed to a person who had Covid-19 in early March), PAIN IN EXTREMITY (Patient received the vaccine in his left arm and had left arm soreness), INTERCHANGE OF VACCINE PRODUCTS (Patient received his first Moderna Covid-19 vaccine on January 9, 2023 and Patient received the second vaccine series dose as the Pfizer vaccine), COVID-19 IMMUNISATION (Patient received his first Moderna Covid-19 vaccine on January 9, 2023 and Patient received the second vaccine series dose as the Pfizer vaccine), PRODUCT AVAILABILITY ISSUE (Patient received the second vaccine series dose as the Pfizer vaccine because the Moderna vaccine was not available to receive) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (The patient did not get his second dose in early February 2023 because he had flu like symptoms, on 11-APR-2023, Patient received the second vaccine series dose as the Pfizer vaccine) outcome was unknown and TENDERNESS (tenderness) was resolving.        For mRNA-1273 (Spikevax) (Unknown), the reporter did not provide any causality assessments.   No concomitant medication was reported.  Patient received his first Moderna Covid-19 vaccine on January 9, 2023 lot number AS7171B Expiration date June 2023. Patient received the vaccine in his left arm and had left arm soreness and tenderness. The patient did not get his second dose in early February 2023 because he had flu like symptoms in early February. The patient was exposed to a person who had Covid-19 in early March however the patient never tested for Covid-19. In late March the patient caught what felt like was a chest cold. His Physician prescribed Azithromycin. More than 28 days after his first dose. The patient was told recently that he could not receive his second dose of the Moderna Covid-19 vaccine because the vaccine was not available. The patient was upset that Moderna did not informed patient who had received their first primary dose of the Moderna Covid-19 vaccine that the second dose would not be available in April. The patient has been looking for his second Moderna dose since Monday. On 11-APR-2023, Patient received the second vaccine series dose as the Pfizer vaccine because the Moderna vaccine was not available to receive. Pfizer lot number FR2583 expiration date was not known. Patient received in his left arm. Patient has a sore left arm.